1-20 of 77 Search Results for

ipilimumab

Sort by
Book Chapter
Series: Current Problems in Dermatology
Volume: 53
Published: 13 November 2017
10.1159/000478081
EISBN: 978-3-318-06101-7
... range of cutaneous AEs observed in patients with advanced melanoma treated with anti-CTLA4 and anti-PD1/PD-L1 antibodies and treatment options for these various cutaneous AEs. Cutaneous Toxicities of Anti-CTLA4 (Anti-Cytotoxic T-Lymphocyte Antigen-4) Antibody Ipilimumab and tremelimumab are fully...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000436998
EISBN: 978-3-318-05590-0
... Coinhibitory Receptors The targets most advanced in development include cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1) and PD-1 ligand 1 (PD-L1; fig. 1 ). The anti-CTLA-4 agent ipilimumab was FDA-approved in 2011 for the treatment of metastatic melanoma based...
Book Chapter
Series: Current Problems in Dermatology
Volume: 53
Published: 13 November 2017
EISBN: 978-3-318-06101-7
...References References 1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723. 2. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al: Nivolumab...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
EISBN: 978-3-318-05590-0
.... 8. Hodi FS, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723. 9. Robert C, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526. 10. Camacho LH, et al: Phase I/II trial...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000437178
EISBN: 978-3-318-05590-0
... of lymphocytes and neutrophils combined with tumor necrosis and vasculopathy. Although some skin toxicity was induced, the single treatment with MDX-CTLA4 (now called ipilimumab) was well tolerated. It took another 7 years before it was demonstrated in a randomized controlled phase III trial, which compared...
Book Chapter
Series: Progress in Tumor Research
Volume: 41
Published: 19 February 2014
10.1159/000355903
EISBN: 978-3-318-02542-2
... that CTLA-4 blockade can enhance immune-mediated tumor rejection when combined with vaccines. Its inhibition with antibodies such as ipilimumab or tremelimumab demonstrated clinical benefit in patients with metastatic melanoma. Fig. 1 Key molecular components of T cell activation by dendritic cells...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000437186
EISBN: 978-3-318-05590-0
... monoclonal antibody ipilimumab has been paired with chemotherapy, specifically a doublet of paclitaxel and carboplatin. In a phase II study, treatment with chemotherapy (paclitaxel and carboplatin) plus a phased application of the anti-CTLA-4 monoclonal antibody ipilimumab significantly improved immune...
Book Chapter
Series: Progress in Neurological Surgery
Volume: 34
Published: 28 May 2019
10.1159/000493057
EISBN: 978-3-318-06422-3
... checkpoint molecule that becomes expressed on the surface of activated cytotoxic T cells and thereby reduces further T cell activation. Ipilimumab is a human immunoglobulin G1 monoclonal antibody against CTLA-4, which activates T cells by blocking the inhibitory function of CTLA-4. Ipilimumab is approved...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
EISBN: 978-3-318-05590-0
... in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712-4717. 11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Haanen JB, Robert C, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723. 12...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
EISBN: 978-3-318-05590-0
..., Bondarenko I, Luft A, et al: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-2054. 15. Reck M, Bondarenko I, Luft A, et al...
Book Chapter
Series: Progress in Tumor Research
Volume: 44
Published: 07 May 2018
EISBN: 978-3-318-06362-2
... immune surveillance to immune escape. Immunology 2007;121:1-14. 8. Teng MW, et al: Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008;84:988-993. 9. Wolchok JD, et al: Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann...
Book Chapter
Series: Progress in Tumor Research
Volume: 41
Published: 19 February 2014
EISBN: 978-3-318-02542-2
... Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782-3793. 3. Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age. Nature 2012;480:480-489. 4. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000436988
EISBN: 978-3-318-05590-0
... will summarise selected studies on immunotherapy in advanced RCC with a focus on anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies. We will only briefly discuss adjuvant therapy and tumour vaccines. Anti-CTLA-4 Therapy Two CTLA-4 antibodies, namely ipilimumab [ 19 ] and tremelimumab [ 20 ], have been...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
EISBN: 978-3-318-05590-0
... with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723. 14. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1...
Book
Book Cover Image
Published: 06 November 2017
10.1159/isbn.978-1-910797-71-6
EISBN: 978-1-910797-71-6
Book Chapter
Series: Advances in Oto-Rhino-Laryngology
Volume: 84
Published: 31 August 2020
10.1159/000457937
EISBN: 978-3-318-06670-8
... there is debate in the literature as to its value. Cervical metastases confer a dramatically worse outcome. Chemotherapy has not previously shown much advantage, but more recently immunologic manipulation with drugs such as ipilimumab have shown promise. Thus far, the mutation status does not appear to affect...
Book Chapter
Series: Progress in Neurological Surgery
Volume: 34
Published: 28 May 2019
EISBN: 978-3-318-06422-3
... capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2015;33:1564–1573. 31. Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010;363:711–723. 32. Robert C...
Book
Book Cover Image
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/isbn.978-3-318-05590-0
EISBN: 978-3-318-05590-0
Book Chapter
Series: Progress in Tumor Research
Volume: 44
Published: 07 May 2018
10.1159/000486981
EISBN: 978-3-318-06362-2
... for certain immune compartments are prone to tumour development and tumour growth [ 7 , 8 ]. Development of Ipilimumab One of the major advances of immunotherapy for cancer was achieved after studying basic mechanisms of T cell function [ 9 ]. CTLA-4 was discovered as an inhibitory molecule on T cells...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000437185
EISBN: 978-3-318-05590-0
.... There are already multiple case reports that indicate an abscopal effect after RT was given in conjunction with ipilimumab, a human monoclonal CTLA-4 antibody [ 44 , 45 , 46 , 47 ]. Both preclinical studies and case reports indicate a beneficial interaction. Theoretically, CTLA-4 inhibition should work well with RT...